Has Ayesha Lall received payments from drug or device companies?

Yes. Drug and device makers reported $4,105 in general payments to Ayesha Lall across 39 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ayesha Lall did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ayesha Lall come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ayesha Lall

Child & Adolescent Psychiatry · Gainesville, FLNPI 1942221031

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,548 of the $4,105 with a category attached, or 62.1%. Boehringer Ingelheim accounts for 70.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $2,752 and has fallen 95.6% since, to $122 in 2025.

$4,105in general payments, 2019–2025

Across 39 payments — averaging $105.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$3K
Eisai Inc.$597
Otsuka America Pharmaceutical, Inc.$173
AbbVie$156
Medtronic$66
Teva Pharmaceuticals USA, Inc.$60
plus $177 from 4 others

$3,555,321in research payments, 2019–2025

Across 322 payments — averaging $11,041 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$1.2M
Eli Lilly$678K
Janssen Research & Development, LLC$494K
Eisai Inc.$425K
Biogen$343K
Otsuka Pharmaceutical Development & Commercialization, Inc.$165K
plus $286K from 11 others

What the payments were for

Travel & lodging$2,54862%
Food & beverage$1,55738%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	7	$2,877
Eisai Inc.	9	$597
Otsuka America Pharmaceutical, Inc.	4	$173
AbbVie(2 entities)	9	$156
Medtronic	1	$66
Teva Pharmaceuticals USA, Inc.	1	$60
Neuronetics, Inc.	1	$59
Shire North American Group Inc	3	$52
Lundbeck LLC	2	$42
Takeda Pharmaceuticals U.S.A., Inc.	2	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ABILIFY MAINTENA$122
ABILIFY ASIMTUFII$122

How this compares

$4,105 in reported general payments places this provider in the 85th percentile of 206 child & adolescent psychiatry providers in Florida.

See all child & adolescent psychiatry providers in Florida →

Other child & adolescent psychiatry in Gainesville

Elias SarkisGainesville$169K
Muhammad SajidGainesville$5K
Amparo Benitez-BroomeGainesville$2K
Craig KuninsGulfport$265K
Jeffrey AlvaroSt Petersburg$87K
Rosa Negron MunozLakeland$39K
Sean HoranMiami$17K
Rachel AgustinesLargo$16K
Carlos BorgeSarasota$15K
Justin SpoonerPonte Vedra Beach$12K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →